Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Aligos Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 41 | 36 | −5 |
| Shares | 26.3M | 25.7M | −554.6K (−2.1%) |
| Value | $25.5M | $19.2M | −$6.30M (−24.7%) |
New holders (2)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Creative Planning | 10,050 | $7.51K | 0.00% |
| Qube Research & Technologies Ltd | 2 | $1 | 0.00% |
Sold out (7)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Deutsche Bank AG | 71,290 | $69.2K |
| Two Sigma Advisers, LP | 52,400 | $50.9K |
| Citadel Advisors LLC | 27,859 | $27.1K |
| Virtu Financial LLC | 18,353 | $18.0K |
| HRT Financial LP | 10,105 | $9.00K |
| Advisor Group Holdings, Inc. | 8,000 | $7.77K |
| Simplex Trading, LLC | 1,189 | $1.00K |